Podcasts about Receptor

Deportes El Nuevo Día presenta una nueva serie de reportajes, titulada "Reyes de la Receptoría", para dar a conocer el trabajo y el desempeño de los receptores boricuas más sobresalientes en la historia de las Grandes Ligas. Conoce de qué se trata junto a nuestro editor de deportes, Carlos Rosa Rosa y el destacado periodista deportivo, Hiram Torraca.

Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension

En este episodio descubrirás el secreto mejor guardado del sistema endocrino: las hormonas no actúan solas, necesitan encontrar su receptor específico. ¿Sabías que puedes tener mucha testosterona o insulina… y aun así no tener efectos? ¿Y que cada hormona tiene una forma diferente de comunicarse con tus células? Hoy aprenderás: Cómo funcionan las hormonas tipo “llave y cerradura” Qué pasa cuando una hormona no encuentra su receptor Diferencias entre hormonas peptídicas, esteroideas y derivadas de aminoácidos Cómo se regula la señal hormonal (y cómo se apaga) Ejemplos prácticos: insulina, testosterona, adrenalina… Este episodio te hará entender por qué tu cuerpo responde o no a una dieta, al entrenamiento o al estrés. Y por qué tu estilo de vida puede ser el verdadero “interruptor hormonal” que lo cambia todo. Spoiler: Tener más hormonas no siempre es la solución. A veces, dormir más y estresarte menos es más hormonalmente inteligente.

Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension

Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension

Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension

Interview with Dennis J. Rivet II, MD, author of GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension. Hosted by Cynthia E. Armand, MD. Related Content: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

Asesinan a periodista en Puebla Guerrero pide declaratoria de desastre en 8 municipios Demócratas ayudan a bloquear ley para destituir a Trump 

In this week's episode, we'll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, or AML; use of megakaryocyte growth factor receptor-based stem cell depletion as part of pretransplant conditioning in ex vivo autologous gene therapy; and identification of an eight-protein risk signature as well as a novel single protein biomarker, soluble oncostatin M receptor, for risk stratification in AML.Featured Articles:Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiacMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pretransplant ConditioningBlood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes

Featuring perspectives from Dr Virginia F Borges, Ms Jamie Carroll, Mr Ronald Stein and Dr Seth Wander, including the following topics: Introduction (0:00) Role of CDK4/6 Inhibitors in Localized and Metastatic Hormone Receptor (HR)-Positive Breast Cancer (12:49) PI3K Inhibition as First-Line Treatment for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) (38:24) Clinical Utility of AKT and PI3K Inhibitors in Progressive HR-Positive mBC (1:01:44) Current and Future Role of Oral Selective Estrogen Receptor Degraders in HR-Positive mBC (1:24:38) NCPD information and select publications

Drs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clinical perspectives and management strategies from nurse practitioners Ms Jamie Carroll and Mr Ronald Stein. NCPD information and select publications here.

Discutimos el futuro de los receptores Rome Odunze en Bears, Jaxon Smith-Njigba en Seahawks y Ladd McConkey en Chargers. =============

BUFFALO, NY - June 4, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 20, 2025, titled “Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells." In this study, authors Shan Lu and Zhongyun Dong from the University of Cincinnati College of Medicine investigated how interfering with a protein interaction could reduce prostate cancer growth. Their study based on prostate cancer cells shows that blocking the link between PCNA, a protein important for DNA repair, and the androgen receptor (AR), which drives prostate cancer growth, can slow down cancer cell multiplication. This discovery could lead to a new treatment for patients with advanced prostate cancer, particularly those no longer responding to hormone therapy. Prostate cancer is one of the most common cancers in men. Many patients eventually become resistant to hormone treatment. In this advanced stage, called castration-resistant prostate cancer (CRPC), tumors continue to grow by using either the full-length androgen receptor (AR-FL) or altered versions called AR variants (AR-Vs). This study shows that the interaction between AR and PCNA helps both AR-FL and AR-Vs remain active, supporting cancer cell survival and growth. The researchers identified a new region in the AR that binds to PCNA. They developed a small peptide, R9-AR-PIP, to mimic this region and block the AR-PCNA connection. They found that this peptide reduced AR's ability to bind DNA and lowered the levels of key genes involved in cancer cell growth. Importantly, the peptide was effective against both types of AR, including the variant forms that are especially challenging in CRPC. “We identified a second PIP-box (PIP-box592) in the DNA binding domain of AR and found that dihydrotestosterone enhances the binding of full-length AR (AR-FL) but not a constitutively active variant (AR-V7) to PCNA.” They also tested a small molecule, PCNA-I1S, which interferes with PCNA's ability to move to the cell nucleus and interact with AR. This molecule showed similar effects as the peptide, reducing AR activity and stopping cancer cell growth. Together, these findings suggest that targeting PCNA/AR interactions could be a promising strategy to fight CRPC, especially in patients with limited treatment options. One key result was that both the peptide and the small molecule reduced the levels of cyclin A2, a protein that helps cells divide and is often overexpressed in CRPC. Since this protein is linked to patients' poor outcomes, its reduction could be especially beneficial. This study improves our understanding of how prostate cancer continues to grow even after hormone treatments fail. By blocking a crucial helper of the androgen receptor, researchers have uncovered a new way to potentially slow or stop the disease. Further studies in animal models are needed, but this approach could lead to more effective treatments for men with advanced prostate cancer. DOI - https://doi.org/10.18632/oncotarget.28722 Correspondence to - Zhongyun Dong - dongzu@ucmail.uc.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28722 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, PCNA, androgen receptor, PCNA inhibitors, AR splicing variants, CRPC To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Dr. Centor discusses the effectiveness and safety of glucagon-like peptide-1 receptor agonists for weight loss in the absence of diabetes with Ms. Areesha Moiz.

In part two of this two-part series, Dr. Stacey Clardy and Dr. Elia Sechi discuss how to approach the management of patients in clinic when there is concern for a possible false positive on the radioimmunoprecipitation assay for the acetylcholine receptor antibody. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213498 

In part one of this two-part series, Dr. Stacey Clardy and Dr. Elia Sechi discuss the clinical scenarios where the commonly used assay for myasthenia gravis is most likely to produce false positive results in patients who do not actually have myasthenia gravis. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213498  

Dr. Stacey Clardy talks with Dr. Elia Sechi about the importance of understanding lab test results, the performance characteristics of assays, and the real-world implications of false positives in myasthenia gravis testing. Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

Encuentra el video completo de este episodio en nuestro canal de YouTube “Piloto Football”

Hey everyone,Fresh out the reactor this week we've got bangers from Transforma, Receptor x Skrimor, TNTKLZ, MEL, Absu_NTQL, Confusion, Saint Rider & more.In Demos, WIPs, and Promos, we're checking out upcoming heaters from Current Value, Magnetude, Skrimor, Mizo & more.It's a bumper episode this week since we missed one last week — get locked in, big love from Ollie! Check out the track list below and let's dive in!Blinded Theory - Pass / Vyugahttps://cygnusmusic.link/knalmayDon't forget you can catch us LIVE recording Stonxcast on Twitch every Friday at 7pm (UK)TRACKLIST AND MORE INFO: www.stonxmusic.co.uk/stonxcast-ep138

Packers eligió a receptor en primera ronda por primera vez desde 2022. ¿Por qué rompieron tradición en el NFL Draft 2025?=============

Featuring an interview with Dr Adam M Brufsky, including the following topics: Case: A woman in her early 50s with ER-positive, HER2-low de novo metastatic breast cancer (0:00) Case: A woman in her late 70s with ER-positive, HER2-low metastatic breast cancer after 5 years of an adjuvant aromatase inhibitor (6:52) Clinical Investigator Survey Results (10:05) CME information and select publications

Dr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast cancer and preexisting medical conditions. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Adam M Brufsky, including the following topics: Mechanism of action of and long-term data with CDK4/6 inhibitors in the management of metastatic breast cancer (mBC) (0:00) Comparing safety profiles of CDK4/6 inhibitors (9:49) Role of CDK4/6 inhibitors in therapy for older patients with mBC (24:06) Real-world evidence with CDK4/6 inhibitors (27:31) CME information and select publications

Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer

Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer

Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer

Hey everyone,Fresh out the reactor this week we've got bangers from Blinded Theory, Screamarts X Enta, 2Whales, Aye Rights & more.In Demos, WIPs, and Promos, we're checking out heaters from the likes of XAETIS, Receptor x Skrimor, Hologram, and Hackwaves & Pezutek.No end mix from our host Ollie this week as he's heading down to London for the Blender 2 Year Anniversary, playing a B2B with XAETIS — big love, see you next week!Blinded Theory - Pass / Vyugacygnusmusic.link/knalmayDon't forget you can catch us LIVE recording Stonxcast on Twitch every Friday at 7pm (UK)TRACKLIST AND MORE INFO: www.stonxmusic.co.uk/stonxcast-ep137

Aaron Rodgers habló sobre su salida de Jets, sus planes de offseason y su posible futuro con Pittsburgh. ¿Debe Steelers pensar en un plan B?=============

We present the seventh episode of Eatbrain Radio Season 2, your guide to the dark side of drum and bass! Grimey, dutty and disgusting all the way! Hosted by @5ha5h label// facebook.com/Eatbra1n twitter.com/eatbrain_now instagram.com/eatbrain eatbrain.net Tracklist // 1. Zigi SC – Recoil [Darkshire Sound] 2. Transforma & Gifta – The Way [Phase Records DNB] 3. Hologram – Crossfire [Eatbrain] 4. Forbidden Society – Kiro [Neksus Sound] 5. BAD SYNTAX – Wildfire (Diode Remix) [Abducted LTD] 6. Screamarts & Enta – Hellhound [Eatbrain] 7. Emperor – Death Tax [Overview Music] 8. Notequal – Echoes [Darkshire Sound, Free Download] 9. Receptor & Skrimor – Red Shift [Evolution Chamber] 10. Ed Rush & Optical – Chubrub (Buunshin Remix) [Patreon Dub] 11. Audio – Flip Mode (Prolix Remix) [Blackout Music] 12. Rift – Sun Skin [C4C Limited] 13. CiDiaH – Gate String [Neuroheadz] 14. Blinded Theory – Vyuga [Stonx Music] 15. PRDK – STARWALKIN [Patreon Dub] 16. Ntechnique & Hellkat – Buran [High Resistance] 17. Rieger – Confession [Paperfunk Recordings] 18. AKOV – Fake Blood [Self Release]

Watch Here : https://www.youtube.com/watch?v=1WV3xTmvPD0 Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog Last time we reviewed why interpreting your lab may lead you to the wrong diagnosis and treatment.  Today we continue our review of each lab panel and why the reference ranges on your lab results may not be the “Healthy Normal Range” that you should compare your results to. Lab reference ranges are established with a one-size-fits-all mentality, ignoring the numerous variables that influence blood results. Have you ever tried on a “one-size-fits-all “ANYTHING? Those clothes may fit 20% of the population but for the rest of us, the garment doesn't fit our width, weight or height! All one-size-fits-all lab reference ranges are much the same.  For example, the standardized “reference ranges” in the US serve as a one-size-fits-all “ideal range” applied to everyone, despite genetic differences, varying latitudes, and the diverse diets that characterize the American multiethnic population. This presents the first problem with using a single range for all people: variations among individuals based on differing genetic needs.  The second issue is that the ranges on the lab report indicate the minimum levels necessary for survival, not necessarily the healthiest blood levels for most individuals. Another example of one size doesn't fit all is the reference range for women's hormones. A range is displayed for cycling women, but there is no healthy range for menopausal women.  Does the range displayed refer to menopausal women with HRT, or menopausal women without HRT to treat their menopausal symptoms? Is the range based on what is healthy, or what is average? We aren't sure. Labs don't ask patients questions that could help interpret lab values. Therefore, they cannot provide a truly diagnostic reference range for any illness. They only consider gender and age, as reference ranges are solely adjusted for these two factors.  A doctor must interpret individual lab results alongside a patient's medical and surgical history, including established diseases, medications, supplements, hormonal treatments, and past lab values. For instance, laboratory companies should offer reference ranges based on whether a patient is menopausal, a woman is undergoing ERT, a man is receiving testosterone, a patient is on thyroid medication, a person is being treated for diabetes, or the diabetic tests are performed to diagnose diabetes.   Some Reference Ranges are Based on comparing results to Misleading formulas The best example of this issue is the Lipid Panel. Doctors use this panel to determine a person's risk for heart attacks caused by atherosclerosis. Most doctors don't know the formula for determining Total Cholesterol. This test doesn't predict heart disease in most patients, as the formula used to arrive at that number is not indicative of the disease. However, doctors have been advised that when   total cholesterol levels are high, a patient should start taking a statin, a drug that reduces blood cholesterol and sometimes lowers the rate of heart attacks in certain individuals, though it is rarely predictive in 50% of the population. The problem with the lipid panel is twofold: the LDL level indicates future atherosclerosis in only about 50% of the population and is not a specific test for future heart disease risk. Total cholesterol is even less predictive of heart disease because it stems from a flawed formula. Doctors interpret a high Total Cholesterol level as an indication that a patient may be at increased risk for heart disease in the future. When I test patients with elevated Total Cholesterol or high levels of LDL using a Cardiac Calcium Scan to measure plaque, only half of them actually produce plaque, and consequently, are not at risk for atherosclerotic heart disease. I believe that the Total Cholesterol number is derived from an inaccurate formula for determining a person's risk of future heart disease. The Total Cholesterol number is calculated using a flawed equation. The equation is as follows:         LDL + 1/5 Triglycerides+ HDL = Total Cholesterol Total Cholesterol = LDL (bad cholesterol) + 1/5 Triglycerides (high risk factor) + HDL (good cholesterol) Let's examine this formula simply like this:   Bad + Bad + Good does not equal Bad. Due to this incorrect formula, thousands, if not millions, of patients have been prescribed statin drugs for a lifetime without justification!  Statins carry risks. The list of side effects is extensive and includes muscle deterioration and statin-associated dementia. Unfortunately, most people who experience statin side effects are women. Women tend to have higher HDL levels than men. Additionally, they typically do not have atherosclerotic plaque until menopause and usually do not develop it after menopause if they undergo estrogen replacement therapy! This gender issue is just one of the problems with laboratory reference ranges that are not adjusted for sex. The total cholesterol values were developed solely from the blood levels of men, who typically have lower HDL levels. Women were excluded from the tests conducted to create this blood panel. For women, I dispel the myth that high total cholesterol predicts heart disease by recommending a Cardiac Calcium Scan to check for plaque. If a woman has no plaque by the age of 50 and is taking estrogen, she is unlikely to develop plaque in the future.  I still test them every 2-3 years to ensure that no metabolic changes have altered their risk, but I don't put much faith in the unreliable cholesterol blood panel. There is another blood test that has deceptive reference ranges: IGF-1 How about the GH-IGF-1 test, the test for Growth Hormone?  IGF-1 is a metabolite of GH that we can measure to determine how much the patient produces.  This hormone aids in healing and replenishing aging cells in patients after their growth is complete.  The healthy normal range with which I was trained, (150-350 MIU), has been changed to an age-adjusted normal that compares a person to others in her age category who had their blood drawn the previous year.  What is wrong with this? Growth hormone (GH) decreases with age and contributes to the declining health people experience as they grow older. Similarly, IGF-1 diminishes with age and illness, which means that the “reference range” essentially reflects that you are “average for the sick individuals who visit Quest to have their IGF-1 levels checked. ” IGF-1 levels can be enhanced through weight loss, testosterone replacement, and an increase in muscle mass. The current reference range does not indicate health or illness; it merely shows whether you fall within the average for your age group. This non-scientific method of determining “health” is widespread in contemporary medicine. By comparing aging individuals to others within the same age group, for hormones that decline with age, based on samples from sick patients who visit a specific lab in the past year, these labs label patients as “healthy” even when they are as ill as other individuals their age who go to that lab! This practice constitutes age discrimination! Regarding hormones, the levels we maintained during our fertile and youthful years correspond to the blood levels indicative of health in all individuals ages. For example: People who check their IGF-1 (Growth Hormone) levels and see a low “52 ng/ml” might feel satisfied that they are within the standard range (50-280 ng/ml). However, they may not realize that this range applies to older, unhealthy individuals, not to healthy young ones (150-350 ng/ml).  This is just one example of the issues that arise when non-medical individuals, who do not monitor these tests regularly, draw conclusions from the numbers.   Some illnesses require more than one blood test for diagnosis If you consider only one of the three tests for diabetes or prediabetes (Fasting Blood Sugar, HbA1c, and Insulin), you cannot self-diagnose as diabetic, prediabetic, insulin resistance or healthy.  Diabetes is a disease that has coincided with the rising number of obese individuals.  Both conditions affect nearly 50% of the American population. Blood tests cannot be interpreted accurately unless a patient has fasted for 12 hours; all three tests should be evaluated. When diagnosing diabetes and insulin resistance, we perform three tests to assess whether a patient has insulin resistance, prediabetes, or diabetes. These tests guide our diagnosis and inform the treatment we provide based on their results. Fasting insulin is a highly misleading test. Over 15 years ago, a significant study was conducted that was believed to change the reference ranges for fasting insulin.  The new range set for normal fasting insulin was less than 10 mIU/ml. By publishing the reference range less than 18 mIU/ml, they miss diagnosing many patients with insulin resistance HBA1C is a test that gives a value of average blood sugar over three months. The results are often used alone to determine prediabetes and diabetes; however, considering all three aspects makes the diagnosis and treatment plan more specific for the patient. FBS (fasting blood sugar) is the third diabetes test. It is generally used as a screening test that prompts the ordering of the other two blood tests; however, some patients exhibit symptoms of diabetes and insulin resistance without having elevated fasting insulin levels. Many medications can raise diabetic test values, causing a patient to seem diabetic when they are actually experiencing a side effect of the drug.  One such medication is Atorvastatin.  The solution is not treating diabetes but rather adjusting the medication.  Hormone tests are especially challenging to interpret, Especially when testing free Testosterone in women Here are the problems with the free Testosterone test itself: Women have extremely low levels of free testosterone and testosterone compared to men. I have been informed by Quest that women's free testosterone levels are not reliable with current methods because they are not always reproducible when a test is conducted twice on the same day. This leads me to believe that hormone levels do not always reflect the actual blood levels of free testosterone and estradiol. The levels of testosterone in women are based on menopausal levels of T. Women have long been thought to not produce testosterone, so the “normal” levels are quite low, and 0 used to be considered normal- until one day I managed to persuade a medical director at Quest to increase it to 0.2! Women's testosterone is influenced by their production of E2 and E1, which inactivate free T. Women vary in how their cells respond to testosterone and estradiol. Receptor sites and their genetic acceptance of hormones can mean that the same blood level of testosterone in both sexes does not produce the same effects in all patients. Some women (and men) are resistant to E2 and T, or to one of the two. This indicates that the hormone-free T level may be optimal for one woman while being ineffective in alleviating any low T symptoms for another. The latter individual is T resistant, and we currently have no means outside of research labs to determine which women are sensitive and which are resistant. This requires that doctors and NPs look beyond typical reference ranges to effectively manage E2 and T replacement for women. Lastly some labs use the total testosterone level through a formula determine the free T. This carries inherent risks of reporting the wrong active level of testosterone. Total and free testosterone blood levels for men, are derived from results of older men, rather than from the blood levels that indicate health and the levels at which men experience no symptoms. This leads men to believe they are normal, even though they are symptomatic, and they can't get treatment. There is no time to discuss the reference ranges for LH, FSH, Estradiol, and Estrone; these topics will be addressed in a future blog. I hope I have encouraged you to review your blood work with your doctor or Nurse Practitioner, and not to act as your own doctor by interpreting your blood tests.

Welcome to the Mind Muscle Connection Podcast!In this episode, I'm excited to welcome back coach and bioengineeringgraduate Calvin Scheller to deep dive into the science of GLP-1, appetiteregulation, and what really happens when using popular medications likeOzempic and Wegovy.Calvin brings his deep academic background and real-world coachingexperience to explore the mechanisms behind GLP-1, the truth behindmuscle loss while using these meds, and how to use them responsiblywithout compromising long-term health.If you've been curious about GLP-1 or are coaching clients who are, thisepisode is packed with science, strategy, and nuance you won't want to miss.Let's talk about:00:45 Introduction3:22 Training Split & Recovery Strategies10:25 Nutrition13:11 What is GLP-125:46 Types of GLP-126:46 Muscle Loss & GLP-129:21 Preserving Muscle during medication43:24 Gut Health53:17 GLP-1 Benefits58:59 Where to find Calvin SchellerCalvin Scheller's Instagram: https://www.instagram.com/calvin_scheller/Follow me on Instagram for more information and education:  @jeffhoehn_FREE 30 Min Strategy Call: HEREBody Recomp Checklist 2.0 HERENutrition Periodization Masterclass: HEREHow You Can Work With Me?: HERECoaching application: HEREBody Recomp Checklist 2.0: https://chipper-producer-6244.kit.com/26b5c9f94a

How do the eligibility criteria for the monarchE and NATALEE clinical trials compare? Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002403?ecd=bdc_podcast_libsyn_mscpedu

Hey everyone,This week, we've got fresh heaters from Manta, Xylym, Nemean, and Xaetis. Plus, we're diving into some epicDemos, WIPs, and Promos featuring Mythic Image, DIODE, Transforma & Paperclip, and the collab from Receptor x Skrimor.Ollie's back to guide you through this week's heavy selection.JIROBASS - Feral Seekers / The Blackwallcygnusmusic.link/w5plrmqDon't forget you can catch us LIVE recording Stonxcast on Twitch every Friday at 7pm (UK)TRACKLIST AND MORE INFO: www.stonxmusic.co.uk/stonxcast-ep134

The rise and rise of Androgen Receptor Pathway (or Signalling) Inhibitors has changed the world of metastatic prostate cancer forever. What was once a cancer with a finite number of treatment options has flourished into a chasm of therapies, many more effective and less toxic than their therapeutic grandparents.Studies discussed in the episode:ARCHESENZAMETFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

A study suggests GLP-1 receptor agonists may reduce hematologic cancer risk in type 2 diabetes patients by 54% compared to insulin. Two individuals have achieved functional HIV cures through stem cell transplants, offering insights into cure strategies. Additionally, women with dense breasts face double the risk of breast cancer and reduced mammogram accuracy, supporting FDA regulations for breast density notifications and additional screening methods.

We have a very important program in store for you this Saturday as The Word on Medicine brings you an information-packed program on the recent explosion of weight loss medications - the so called GLP-1 receptor agonists. Our panel of experts includes Drs. Lisa Morselli, Tammy Kindel, Kate Glasenapp, and Aimee Welsh and in the last segment, one of Dr. Kindel's patients will join for the all-important patient perspective. There is so much information (and misinformation) on this class of medications - - you will not want to miss this program.

Seahawks favorito para firmar a Cooper Kupp, Giants entrevista a Joe Flacco y Russell Wilson; y más noticias de agencia libre NFL 2025.=============

A paralyzed man is able to move a robotic arm using only his thoughts with the help of AI and how the brain cannabinoid receptor is linked to stress. Plus, on This Day in History, we take a look at the Gold Standard Act. Paralyzed Man Moved a Robotic Arm Using Only His Thoughts Thanks to AI. It Kept Working for Months | ZME Science Brain Receptors For Cannabis Could Be Why Some People Are More Resilient : ScienceAlert Brain Cannabinoid Receptor Linked With Stress Resilience in Mice Astocyte endocannabinoid receptor and BBB linked with stress resilience | GEN Astrocytic cannabinoid receptor 1 promotes resilience by dampening stress-induced blood–brain barrier alterations | Nature Neuroscience What Is the Gold Standard? History and Collapse | Investopedia Contact the show - coolstuffcommute@gmail.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Welcome back Rounds Table Listeners! We are back today with our Classic Rapid Fire Podcast! This week, Drs. Mike and John Fralick discuss two recent papers examining the effect of glucagon-like peptide-1 receptor agonists (GLP1's) on patients living with Parkinson's disease. Two papers, here we go!Trial of Lixisenatide in Early Parkinson's Disease (0:00 – 10:24).Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease (10:25 – 17:40).And for the Good Stuff:Port Blandford artist creates portraits from Scotch tape (17:41 – 18:33).Rheumatology for the Royal College podcast (18:34 – 19:42).This episode is sponsored by Northern Ontario Resident Streamlined Training and Reimbursement Program (NORSTAR). Check out details here!Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

In part two of this two-part series, Dr. Vikram Karnik and Dr. Lorraine Kalia discuss the preclinical data and epidemiological data that led us to the phase three study on exenatide. Show reference: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00161-8/abstract  

Dr. Vikram Karnik talks with Dr. Lorraine V. Kalia about the potential role of GLP-1 receptor agonists in neurodegenerative diseases, the current state of research, preclinical evidence, and future directions for GLP-1 agonists. Read the related article in The Lancet. Disclosures can be found at Neurology.org.  

In part one of this two-part series, Dr. Vikram Karnik and Dr. Lorraine Kalia discuss recent clinical trials on exenatide as a disease-modifying therapy for Parkinson disease. Show reference: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00161-8/abstract 

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Kevin Kalinsky, a leading breast medical oncologist and director of the breast cancer program at the Winship Cancer Institute of Emory University. Join us as we dive deep into the complexities of hormone receptor-positive breast cancer treatment. We discuss the latest advancements in treatment algorithms, including the use of OncotypeDX in premenopausal versus postmenopausal women, the role of ovarian function suppression, and the implications of new approvals like Inavolisib and CDK4-6 inhibitors. Key topics covered in this episode: •⁠  ⁠The significance of recurrence scores in dictating adjuvant chemotherapy •⁠  ⁠The ongoing OFSET trial and its potential impact on treatment decisions •⁠  ⁠Insights into the use of genomic assays like MammaPrint and RS-Clin •⁠  ⁠The evolving landscape of treatment options for locally advanced and metastatic breast cancer •⁠  ⁠The latest on PARP inhibitors, T-DXd, and other novel therapies Whether you're a medical professional or someone interested in the latest in oncology, this episode is packed with valuable insights and clinical pearls. Don't forget to subscribe for more discussions on cancer treatment, FDA approvals, and conference highlights! YouTube: https://youtu.be/_icBN3J3Bc0 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers #OncologyBrothers #HR+ #breastcancer   #HormoneReceptorPositiveCancer #oncbrothers  #Podcast

Davante Adams quiere jugar en la costa oesta, Commanders busca nuevo corredor y más noticias rumbo a la agencia libre NFL 2025.=============

A new phase 3 trial demonstrated that adding nivolumab to adjuvant chemotherapy significantly improves outcomes for patients with ER-positive HER2-negative breast cancers. Heavy lifetime cannabis use was associated with reduced brain activity in areas responsible for working memory, suggesting potential long-term cognitive impacts. A study found that EMS clinicians wearing ballistic vests experienced higher rates of workplace violence and increased patient refusal of treatment, particularly among racial and ethnic minority patients.

Discutimos la agencia libre de Tee Higgins, Chris Godwin y Cooper Kupp. También analizamos el Super Bowl 59 con Mike Guerrero.=============

Welcome to a monumental celebration in the world of Drum and Bass with The Stress Factor Podcast episode 320, marking a remarkable 15-year journey since its inception on January 1, 2010. This special episode is a thrilling 60 track studio mix by the renowned DJ B-12, designed to take listeners on an exhilarating auditory adventure. Spanning an impressive hour and 43 minutes, the mix showcases the finest in current upfront, liquid, and electro Drum and Bass, featuring euphoric vocals and stunning melodies that will resonate with both long time fans and newcomers alike. The energy is palpable, and the carefully curated selection of tracks promises to elevate your spirits and keep you moving, making it a perfect soundtrack for any occasion. As a heartfelt thank you to the loyal listeners who have supported The Stress Factor Podcast over the years, this episode is a testament to the community that has grown around it. Special acknowledgments go out to DJ Scottie B and Ste-J, who have been integral to the show since its early days, as well as DJ Tribo and R1 for their invaluable contributions. The episode features minimal talking, allowing the music to take center stage, but it does include a special voice message from the podcast's number one VIP listener, Axel The X Engler, adding a personal touch to this celebratory mix. With plans for a highly anticipated best of mix in February, the excitement continues as The Stress Factor Podcast looks forward to another 15 years of delivering the best in Drum and Bass. Big ups to all who have been part of this incredible journey! This episode contains tracks and remixes from the following artists and on the following labels Makoto, Lauren Archer, Liquicity Records, Nkz, Lizplay Records, Nicky Romero, Vikkstar, Alpharock, Oaks, Rameses B, Protocol Recordings, Genemo, YUNA, Saralia, Munix Records, Freaks Geeks, Flowidus, Gia Santho, Elevate Records, AL SO, Plasmator, Manifest, Andromedik, Lauren L'aimant, Akos Gyorfy, Kelle, Celsius Recordings, Friction, Circadian, Fallen State, Mathematica Records, Kleu, LoveThatBass, Receptor, Paperclip, Paperfunk Recordings, Voicians, Gentlemens Club, Lee Mvtthews, DnB Allstars, Marble Elephant, Monika, Spearhead Records, Cyazon, Gracie Van Brunt, Bassrush Records, K2T, DA TU, Offworld Recordings, Technimatic, Zara Kershaw, Keeno, Polaris, Keeno Music, Koven, AEON MODE, Monstercat, Modest Intentions, Formulus, Park Shadow, Straight Up Breakbeat, Rene Lavice, Felix Samuel, DeVice, Bloque, Blean, Interstellar Audio, S.P.Y, ALIBI, flowanastasia, Shogun Audio, Lexed, MAD1AD, Etherwood, UKF, InMost, Fae Vie, Telomic, DuoScience, Rezilient, Dux n Bass, EPITOME, LMX, Kubiks, Pyxis, Alpha Rhythm, Goldfat Records, Hybrid Minds, Lyvia, Melic, DistroKid, Close Inside, Dihanie, Ninkid, Perfect Pitch, Solar Vision, You Love Dance, Sam M, Ridmic, Jolliffe, Sydney Bryce, DrumAndBassArena, Lee Mvtthews, Kate McGill, DIMOD, BazAan, T And Sugah, Amber Jay, Feint, Maduk, Tengu, YosH, Artificial Intelligence, Genetics, Amber Jay, Holy Polly, NMA, Frameshift, Twintone, DNBB Digital, Wardown, Blu Mar Ten Music, Future Shock, Impact Music, Liquefaction, LW Recordings. Tracklist 01. Makoto Ft. Lauren Archer - Invincible [Liquicity Records] 02. Nkz - Bye Bye Darling [Lizplay Records] 03. Nicky Romero x Vikkstar x Alpharock x Oaks - Where Do I Go (Rameses B Extended Remix) [Protocol Recordings] 04. Genemo, YUNA and Saralia - Let Go (Goodbye) [Munix Records] 05. Freaks and Geeks, Flowidus and Gia Santho - Out My Head [Elevate Records] 06. ALSO and Plasmator - Open Your Eyes [Manifest] 07. Andromedik - Air (ft. Lauren L'aimant) [Andromedik] 08. Akos Gyorfy and Kelle - Bastard [Celsius Recordings] 09. Friction - Remember (Circadian Remix) [Elevate Records] 10. Fallen State - What You've Done [Mathematica Records] 11. Kleu - Fading Away (Dub Mix) [LoveThatBass] 12. Receptor and Paperclip - Long Story [Paperfunk Recordings] 13. Voicians - Back In Time [Liquicity Records 14. Receptor - Maybe You Could [Paperfunk Recordings] 15. Gentlemens Club and Lee Mvtthews - Frequency [DnB Allstars] 16. Marble Elephant - Melancholia [Celsius Recordings] 17. Fallen State - Open Mind [Mathematica Records] 18. Monika - Joanna [Spearhead Records] 19. Cyazon and Gracie Van Brunt - My Way Out [Bassrush Records] 20. K2T & DA TU - Unwavering Spirit [Offworld Recordings] 21. Technimatic - Only Dreamers (ft. Zara Kershaw) [Technimatic Music] 22. Keeno - Lights On (Polaris Remix) [Keeno Music] 23. Koven and AEON MODE - Polarised [Monstercat] 24. Modest Intentions and Formulus - Magnetize [Liquicity Records] 25. Park Shadow - Breach [Straight Up Breakbeat] 26. Andromedik - Time [Liquicity Records] 27. Rene Lavice ft. Felix Samuel - Count On You (Extended Mix) [DeVice] 28. Bloque and Blean - The Descent [Interstellar Audio] 29. S.P.Y x ALIBI x flowanastasia - This Is Goodbye [Shogun Audio] 30. Lexed, MAD1AD - It's Not Over [Manifest] 31. Etherwood - Sinking Sand [UKF] 32. Keeno x InMost x Fae Vie - To Feel OK Again (Telomic Remix) [Keeno Music] 33. DuoScience and Rezilient - Tread Lightly [Celsius Recordings] 34. Dux n Bass - Shootingstars [EPITOME] 35. Andromedik - Nothing Like You [Liquicity Records] 36. LMX and Kubiks - See Through [Liquicity Records] 37. Pyxis and Alpha Rhythm - Wanna Say Goodbye [Goldfat Records] 38. Hybrid Minds and Lyvia - Tear Drops [UKF] 39. Melic - Again [DistroKid] 40. Close Inside - Hybrolife [Dihanie] 41. Ninkid, Perfect Pitch and Solar Vision – The Power of Love [You Love Dance] 42. Marble Elephant - Carbon [Celsius Recordings] 43. Sam M - Close To The Edge [Ridmic] 44. Jolliffe and Sydney Bryce - Everything I Know [DrumAndBassArena] 45. Pyxis and Alpha Rhythm - Hummingberg [Goldfat Records] 46. Lee Mvtthews and Kate McGill - Take Me Anywhere [Elevate Records] 47. DIMOD and BazAan - Call Me [Lizplay Records] 48. T and Sugah - Euphoria (ft. Amber Jay) [Liquicity Records] 49. Scatterbrain and HumaNature - Second Thoughts (Subliminal Remix) [Fokuz Recordings] 50. Feint - Divided Sky [Liquicity Records] 51. Maduk - Stay Like This (Telomic Remix) [Liquicity Records] 52. Tengu x Emma Cannon - Coming Back To Me [YosH] 53. Artificial Intelligence and Makoto - Cold Expanse [Liquicity Records] 54. Genetics and Amber Jay - Escape [Ridmic] 55. Holy Polly - Breathe In [NMA] 56. Frameshift and Twintone - For Want Of You [DNBB Digital] 57. Wardown - And They Fell [Blu Mar Ten Music] 58. Future Shock - Alone Again [Impact Music] 59. Liquefaction - Tell Me [LW Recordings] 60. Wardown - No New Messages [Blu Mar Ten Music]